Paper Details

  1. Home
  2. Paper Details

Effects of triple-drug therapy with nitazoxanide, high-dose ribavirin and peginterferon-α-2a in patients with chronic hepatitis C.

Author: BasuP Patrick, BrownRobert S, KrishnaswamyNithya, RayapudiKrishna, ShahNiraj James

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated a novel three-drug regimen for chronic hepatitis C virus infection, using nitazoxanide and high-dose ribavirin as lead-in therapy followed by PEG IFN-α-2a in triple therapy.
Paper Details　
Original Abstract of the Article :
The historical standard of care for patients with chronic hepatitis C virus (HCV) was peginterferon (PEG IFN) and ribavirin combination therapy, yielding sustained virological response (SVR) rates of 38-52% in HCV genotype 1 patients. This study evaluated a novel three-drug regimen of nitazoxanide a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/hepr.12013

データ提供：米国国立医学図書館（NLM）

Triple-Drug Therapy for Chronic Hepatitis C: A New Oasis in the Desert of Treatment Options

The landscape of [chronic hepatitis C virus (HCV)] treatment is constantly evolving, and researchers are continually seeking new and effective therapies. This study examines the effectiveness of a novel [triple-drug regimen] in patients with [chronic hepatitis C]. The authors investigated the combination of [nitazoxanide], [high-dose ribavirin], and [peginterferon-α-2a] and found that this approach demonstrated promising results in terms of achieving [sustained virological response (SVR)].

A Powerful Combination for Fighting HCV

This study offers a new beacon of hope in the desert of [HCV] treatment. The findings suggest that a [triple-drug regimen] combining [nitazoxanide], [high-dose ribavirin], and [peginterferon-α-2a] could be a powerful tool in the fight against [chronic hepatitis C]. This approach offers a potentially more effective alternative to traditional treatment strategies, leading to improved patient outcomes.

Navigating the Desert of HCV Treatment

The desert of [HCV] treatment can be challenging, but this study provides a glimmer of hope. The promising results of the [triple-drug regimen] offer a new path toward [SVR] and a healthier future for patients battling this disease.

Dr.Camel's Conclusion

The journey through the desert of HCV treatment is often long and arduous, but with the right tools and strategies, patients can find a path to a healthier future. This study highlights the potential of a triple-drug regimen as a powerful weapon against HCV, offering a new oasis of hope for those facing this disease.

Date :
  1. Date Completed 2013-06-05
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

23228134

DOI: Digital Object Identifier

10.1111/hepr.12013

Related Literature

Article Analysis
・Effects of nitazoxanide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.